Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

121.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
NASDAQ:JAZZ is an undervalued gem with solid fundamentals.
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and... 
Via Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile. 
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals. 
Via Chartmill
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying. 
Via Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
Via Benzinga
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone. 
Via Benzinga
Exposures Product Safety
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year. 
Via Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5! 
Via The Motley Fool
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them. 
Via Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... 
Via Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
Via Benzinga
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
Via Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Via Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
The 3 Best Cannabis Stocks to Buy in August 2024
Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
Via InvestorPlace
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.